Date: November 14, 2026

Ref: - GHL/2026-27/EXCH/78

The General Manager
Dept. of Corporate Services
BSE Limited, P J Towers,
Dalal Street, Mumbai - 400 001

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051

Scrip Code: 543654

Symbol: MEDANTA

Sub: Analysts/Investors Meet- Presentation

Dear Sir(s),

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in continuation of our letter no. **GHL/2026-27/EXCH/76/77 dated November 10, 2026** regarding the Analysts/Investors Meet scheduled to be held on **November 16, 17, 19 and 20, 2026,** enclosed herewith is a copy of the presentation proposed to be discussed during the aforesaid Meetings.

The above details will also be available on the website of the Company at www.medanta.org under Investor Relations section.

Kindly take the above on record.

For Global Health Limited

RAHUL RANJAN
Digitally signed by RAHUL RANJAN
Date: 2026.11.14 12:13:26 +05'30'

Rahul Ranjan
Company Secretary & Compliance Officer
M. No. A17035

GLOBAL HEALTH LIMITED

Dedicated to Life











Investor Presentation

November 2026

Disclaimer

- This presentation, apart from historical information, contains some "forward-looking statements" including those describing the Company's strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by these statements. These factors include, but are not limited to general market conditions, macro-economic, movements in currency exchange and interest rates, the ability to attract and retain high quality human resource, competitive pressures, technological developments, governmental and regulatory trends, legislative developments, and other key factors beyond the control of the Company.

- These forward looking statements are based on information currently available to us, and we assume no obligation to revise these statements as circumstances change. The Company may alter, modify or otherwise change in any manner the content of Presentation/Press Release, without obligation to notify any person of such revision or changes.

Contents

01 Q2 and H1 FY2027 Performance Update

02 Project Update and Capex Plan

03 Medanta's Journey, Purpose and Model of Healthcare

04 Annexures

01

Q2 and H1 FY2027 Performance Update

Q2 FY2027 performance summary

Revenue Growth of 34% y-o-y driven by growth in patient volumes

Revenue from operations

INR 14,690 million

Q2 FY26
10,993 million

▲ **33.6%**

Operating EBITDA[1] and Margins %

INR 3,701 million
Margin: 25.2%

Q2 FY26
2,310 million
Margin: 21.0%

▲ **60.2%**

PAT and Margins %

INR 2,191 million
Margin: 14.9%

Q2 FY26
1,584 million
Margin: 14.4%

▲ **38.3%**

Occupied Bed Days

190,600

Q2 FY26
155,729

▲ **22.4%**

ARPP* (INR Lakh)

2.06

Q2 FY26
2.01

▲ **2.7%**

ALOS (days)

2.89

Q2 FY26
3.06

▼ **-5.5%**

Patient Footfalls (in '000)

66
In-patients

▲ **29.5%**

Q2 FY26
51

1,229
Out-patients**

▲ **37.9%**

Q2 FY26
891

1. Operating EBITDA is defined as EBITDA excluding other income and after accounting for ESOP expenses. The comparative figures have also been presented on a consistent, like-for-like basis
*ARPP is calculated on Hospital Revenues excluding Other Operating Income and other income divided by Inpatient Volumes;
**Outpatients volume reflects OPD encounters

Q2 FY2027 performance summary

Revenue Growth of 34% y-o-y, primarily led by increase in patient volumes

- Q2FY27 revenue from operations of INR 14,690 million; growth of 33.6% y-o-y
- Operating EBITDA grew 60.2 % y-o-y to INR 3,701 million with improved margins of 25.2% in Q2 FY27 compared to 21.0% in Q2FY26.
- Noida hospital witnessed revenue from operations of INR 1,059 million and EBITDA of INR 86 million in Q2 FY27
- Profit After Tax was INR 2,191 million, compared to INR 1,584 million in Q2FY26. PAT margins were at 14.9% compared to 14.4% in Q2 FY26
- During the quarter, total 74 new beds were added across the network; 25 beds were added at Lucknow and 49 beds in Noida
- Medanta continues to witness robust volume growth, In-patient count grew by 29.5% while Out-patient count grew by 37.9% y-o-y
- With the addition of beds across the network over the last 18 months (including Noida launch), Medanta's Census bed capacity stood at 3,115 in Q2FY27 compared to 2,658 beds in Q2FY26.
- Occupied bed days increased by 22.4% y-o-y, representing an occupancy of ~67% on increased bed capacity compared to 64% in Q2FY26.
- Average revenue per patient (ARPP) for the quarter was INR 2.06 lakh compared to INR 2.01 lakh in Q2FY26
- Average length of stay (ALOS) for the quarter was 2.89 days compared to 3.06 days in previous corresponding quarter
- Cluster 1 hospitals (Gurgaon, Indore and Ranchi) reported revenue from operations of INR 8,229 million in Q2FY27, growth of 17.8% y-o-y. Operating EBITDA was INR 1,810 million, growth of 29.1% y-o-y; Operating EBITDA margin expanded to 22.0% from 20.1% in Q2FY26.
- Cluster 2 hospitals (Lucknow, Patna and Noida), reported revenue from operations of INR 5,790 million, growth of 63.2% y-o-y. Operating EBITDA increased by 110.0% y-o-y to INR 1,837 million, with margins improving to 31.7% compared to 24.7% in Q2FY26
- During the quarter, International Patients Revenue increased by 30.3% y-o-y to INR 993 million
- OPD Pharmacy (Hospital & Retail) business continues to witness robust growth. Revenue increased by 52.9% y-o-y to INR 699 million in Q2 FY27

1. EBITDA represents EBITDA before ESOP expenses

Q2 FY2027 Business update

Strengthening the Core and Building a Robust Pipeline for Sustainable Growth

Capacity Expansion

- ✓ **Noida:** Added 49 beds; total operational capacity at 482 beds
- ✓ **Lucknow:** 25 beds added, taking total bed capacity to 803 beds
- ✓ **Ranchi:** Launched Medical Oncology services
- ✓ **Gurugram:** 2 New OTs and 1 new Cath Lab added during the quarter
- ✓ **Ghaziabad:** Allotted 2.61 acre land parcel in an e-auction for INR 1,658.2 mn

Attract Best Talent

- ✓ **100+ Doctors on-boarded** in Q2 FY27 across Medanta network hospitals
- ✓ **65+ senior clinicians** on-boarded during the quarter

New Medical Equipment Deployed

Gurugram	Patna	
		
Artis Icono Biplane Lab	Siemens Artis ceiling-mounted cath lab	VELYS Hip Navigation Station SAT Station BAS Station


Continuity of Care

- ✓ **850+ active collection centres** across 120+ cities supported by 13 labs and 7 HLMs /RLMs
- ✓ **Added 6 pharmacies during the quarter**, expanding the network to 28 operational pharmacies
  (7 Hospital, 4 Medi-clinics and 17 Retail Pharmacies)


Medanta Noida operational with 482 beds

Noida operations demonstrating strong momentum, with EBITDA breakeven achieved during Q2 FY27

Revenue from operations (INR million)



Operating EBITDA[1] (INR million)




1. Operating EBITDA is defined as EBITDA excluding other income and after accounting for ESOP expenses. The comparative figures have also been presented on a consistent, like-for-like basis.


Key operating metrics: Revenue and profitability

Operating EBITDA in Q2 and H1 grew by 60% and 43% y-o-y, respectively

Revenue from operations (INR million)



Operating EBITDA[1] (INR million and margin %)




1. Operating EBITDA is defined as EBITDA excluding other income and after accounting for ESOP expenses. The comparative figures have also been presented on a consistent, like-for-like basis


Key operating metrics: Profitability and margin

Q2 PBT and PAT growth of 48% and 38% y-o-y, respectively

Profit before tax (INR million and margin %)



Profit after tax (INR million and margin %)




*Q2FY26 and H1FY26 PBT includes a non-recurring exceptional income of INR 160 million and INR 356 million, respectively, on account of 1) reversal of potential interest liability on EPCG following transfer of EPCG licenses from MHPL to GHL amounting to INR 196 million (accounted in Q1FY26) and 2) reversal of stamp duty payable on account of the merger of MHPL with GHL, amounting to INR 159.85 million pursuant to adjudication of its stamp duty application (accounted in Q2FY26).


Key operating metrics: Volumes, occupancies, ALOS

Q2 FY27 witnessed 17% expansion in census bed capacity enabling strong IPD volume growth of 30% y-o-y


Average census and occupied beds per day




ALOS (days)



IPD volumes (in '000)



OPD volumes* (in '000)




** OPD volumes reflects OPD encounters*


Key operating metrics: ARPP and revenue mix

ARPP growth driven by change in case and payor mix


ARPP* (INR Lakh)




IPD Revenue mix by payor category**



Domestic and international revenue mix




IPD vs OPD revenue mix



* ARPP is calculated on Hospital Revenues excluding Other Operating Income and Other Income divided by Inpatient Volumes
** IPD revenue mix by payor category is based on payment type

Diverse revenue[1] mix

Significant contribution from complex specialties




Notes:
1. Revenue from healthcare services excludes other operating income and other income
2. Revenue breakdowns are provided as per internal MIS at the Company's consolidated level
3. Cancer includes medical oncology, radiation oncology, head & neck surgery, bone marrow transplant and breast surgery

Cluster 1 hospitals - Consistent Growth with Improved Margin


Growth in cluster-1 hospitals led by both patient volume and case mix change

Cluster 1 hospitals – Gurugram, Indore and Ranchi


Revenue from operations (INR million)




Operating EBITDA (INR million and margin %)




In-patient Volume (In '000)




ALOS (days)



Occupied Bed Days (count)



ARPP* (INR Lakh)



*ARPP is calculated on Hospital Revenues excluding Other Operating Income and Other Income divided by inpatient volumes


Cluster 1 (previously referred to as "Mature Hospitals") comprises Gurugram, Indore and Ranchi hospitals. The grouping has been renamed for presentation purposes, with no change in the underlying composition.

Cluster 2 hospitals - Robust Growth with Improved Margin


Inpatient volume growth of 52% and ARPP growth of 8% led to strong revenue and EBITDA growth

Cluster 2 hospitals – Lucknow, Patna and Noida


Revenue from operations (INR million)




Operating EBITDA (INR million and margin %)




In-patient Volume (In '000)




ALOS (days)



Occupied Bed Days (count)



ARPP* (INR Lakh)



*ARPP is calculated on Hospital Revenues excluding OPD Pharmacy and Other Income divided by inpatient volumes

Cluster 2 (previously referred to as "Developing Hospitals") comprises Lucknow, Patna and Noida hospitals. The grouping has been renamed for presentation purposes, with no change in the underlying composition.

Financial performance: Medanta Pharmacy and Labs

OPD Pharmacy (Hospital & Retail)


28 operational pharmacy outlets comprising of:

- ✓ 7 Hospital Pharmacies
- ✓ 4 Medi-clinics
- ✓ 17 Retail Pharmacies
  - Gurgaon- 9
  - Lucknow - 7
  - Noida – 1


Medanta Labs

120+ Cities of Operation	**330+** Partner-run Collection Centres (FOFO)	**9** Company owned collection centres (COCO)
850+ Pick Up Points (PUPs)	**13** Labs	**7** HLM & RLM

Revenue – OPD Pharmacy Business (INR million)



Revenue – Lab Business (INR million)



H1 FY2027 Balance sheet summary

Well capitalized balance sheet and strong EBITDA to cash flow conversion

INR millions	FY2023	FY2024	FY2025	FY2026	H1 FY2027
Gross Debt	8422	4,193	3,279	6,311	**6,949**
Cash and Cash Equivalents	13,114	11,913	11,402	12,217	**14,765**
Net Debt / (Net Cash)	**(4,692)**	**(7,720)**	**(8,123)**	**(5,906)**	**(7,815)**
Shareholder Equity	24,282	29,056	33,864	39,616	**43,234**
Net Debt to Equity (x)	**-**	**-**	**-**	**-**	**-**
Net Cash flow from Operations	6,445	6,121	6,238	7,144	**5,678**
Operating EBITDA[1]	6,278	7,991	8,771	9,191	**6,568**
Cash Flow Conversion (%)	**102.7%**	**76.6%**	**71.1%**	**77.7%**	**86.4%**
Net Debt to EBITDA (x)	**-**	**-**	**-**	**-**	**-**

Key Highlights

- Gross Debt increased by INR 638 million
- Net Cash surplus of INR 7,815 million at the end of 30 September, 2026
- Medanta continues to generate strong operating cash flows, supported by robust EBITDA-to-cash flow conversion of 86% in H1 FY27
- Capex of INR 3,385 million incurred during H1 FY27
- Well capitalized balance sheet to drive future expansion plans and growth

1. Operating EBITDA is defined as EBITDA excluding other income and after accounting for ESOP expenses. The comparative figures have also been presented on a consistent, like-for-like basis


02

Project Update and Capex Plan

On-going expansion projects

~20% Capacity added in FY26. Planned bed capacity addition to drive sustainable growth

Number of installed beds




- **Noida with total capacity of 550 beds:** 100 beds added in H1 FY27, taking total bed count to 482 beds at the end of September 2026
- **Lucknow:** 46 Beds added in H1 FY27 taking total bed count of 803 beds.
- **South Delhi:** Announced 400 bed in partnership with DLF. Construction is in progress on site 1.
- **Pitampura, New Delhi:** O&M Agreement to jointly build and operate & manage a ~750 bed hospital. Revised building plans to be submitted in line with revised NBC standard 2026
- **Mumbai:** Environmental clearance and Consent to Establish received. Piling works for the substructure commenced
- **Guwahati, Assam:** Land acquisition completed. Key statutory approvals secured, including Fire, Environmental and Building Plan. On-boarded Consultants for MEP, Facility Planner, and Architecture.
- **Varanasi:** 400-bed project announced in March 2026 under built to suit and lease arrangement with developer. Building plans submitted for approval.
- **Indore Cancer Unit:** Addition of an 80-bed cancer hospital under business transfer agreement, to be operationalized in Q3 FY27
- **Ghaziabad:** 2.61 acre land parcel allotted in an e-auction. Plan to build ~500 bedded super specialty hospital


Estimated capex plan

Total capex of ~INR 62,390 million planned for next 4 - 5 years

Project wise capex (INR mn)



Year wise estimated capex (INR mn)



03

Medanta’s Journey, Purpose and Model of Healthcare

Medanta was founded to bring a new type of healthcare to India...

... the human side of healthcare

Healthcare is never only about science. It is also about the art of medicine – the human connection, putting the patient first, collaboration, the personal acts of empathy and the values that guide our decision making.

"At Medanta we have built an institution to match the highest benchmarks of excellence globally. We have created an ecosystem of excellence that encompasses world-leading clinicians, state-of-the-art equipment, best-in-class infrastructure, and a strong emphasis on research and innovation.

Medanta's patient-first approach allows teams of super-specialist doctors to collaborate seamlessly and arrive at the best-possible treatment customized for each patient in line with our guiding philosophy 'Har Ek Jaan Anmol', meaning 'Every Life is Invaluable'"



Dr. Naresh Trehan
CMD & Chief Cardiac Surgeon, Medanta

Growth from a single flagship hospital in Gurgaon...

...to a network of 6 high quality hospitals across north India



2009
MEDANTA
THE MEDICITY
Gurgaon
1,440 Beds
316 ICU Beds



2014
MEDANTA
SUPER SPECIALTY
HOSPITAL
INDORE
175 Beds
53 ICU Beds

2013
Carlyle* buys
minority stake in
December



2015
MEDANTA ABDUR
RAZZAQUE ANSARI
MEMORIAL WEAVERS
HOSPITAL
RANCHI
200 Beds
54 ICU Beds



2019
MEDANTA
HOSPITAL
LUCKNOW
950 Beds
803 currently
operational
including 211 ICU
beds

2015
Temasek buys
minority stake in
January



2021
JAI PRABHA
MEDANTA SPECIALTY
HOSPITAL
PATNA
650 Beds
601 currently
operational including
176 ICU beds

IPO

2022
Global Health Ltd
IPO listed on BSE
and NSE on 16th
November*



2025
MEDANTA
HOSPITAL
Ranchi Unit 2
110 Beds
Commenced
operations
in July 2025



FY2026
MEDANTA
HOSPITAL
NOIDA
550 Beds
482 currently
operational
including 98 ICU
beds

- *Carlyle Group (Anant Investments) exited completely in the IPO

From our flagship Medicity campus in Gurgaon, we have grown to 3,811 beds across 6 cities

Largest private hospital beds in operation under one roof in Delhi (NCR), Uttar Pradesh and Bihar



Gurgaon
1,440 beds; 316 ICU beds



LUCKNOW
803 beds; 211 ICU beds (950 planned)



PATNA
601 beds; 176 ICU beds (650 planned)



INDORE
175 beds; 53 ICU beds



RANCHI
310 beds; 102 ICU beds



NOIDA
482 beds; 98 ICU beds (550 planned)

All beds are installed beds as at Sept 30, 2026

Bringing the Medanta standard to underserved areas

Medanta Gurugram: One of the largest single location private hospital in India

1,440 beds
40+ OTs
316+ ICU beds
JCI & NABH Accredited



Bringing the Medanta standard to underserved areas

Medanta Lucknow: delivering high quality healthcare to the 220 million people of UP since 2020

803 beds open (950 planned)
20 OTs
210+ ICU beds
JCI & NABH Accredited



Bringing the Medanta standard to underserved areas


Medanta Patna: Opened in January 2022, EBITDA break even in first year



Bringing the Medanta standard to underserved areas


Medanta Noida: Formally inaugurated in November 2025

482 beds open(550 planned)
16 OTs
98 ICU beds
NABH Accredited



One of the largest private hospital chains in North and East India

Serving over 400 million people in the States with Medanta facilities



Our Network

Hospital Network

6 Multi-speciality hospitals

6 Upcoming hospitals

Bed Capacity

3,811 Total Beds

~3,800 Planned Bed Addition

Infrastructure

955+ ICU Beds

110 Operating Theatres

Continuity of care

Medanta Clinics

12 Clinics

7 cities

Medanta Labs

13 Labs total

850+ Pick Up Points

Pharmacy

28 Pharmacy

Our People

Doctors

2,580+

Nurses and paramedics

8,210+

Full-time and retainer employees

14,500+

Existing Hospital : 1. Gurugram, 2. Indore, 3. Ranchi, 4. Lucknow 5. Patna 6. Noida
Upcoming Hospitals: 1.Mumbai, 2. Pitampura, New Delhi 3. South Delhi, 4. Guwahati, 5. Varanasi, 6. Ghaziabad

Our Mission and Values

Embracing a new era and redefining our purpose

MISSION

Our mission is to deliver world class, patient centric, integrated and affordable healthcare through a dynamic institution that focuses on the development of people and knowledge

Core Values



Patient centric care: Foster a culture where every one of us is committed to care for patients and their caregivers



Leadership and quality: Commit to delivering excellence in everything we do through exemplary action and behaviour




Integrity and courage: Maintain the highest ethical standards by putting the patient first and demonstrating the courage to do what is right



Collaboration, learning and innovation: Promote teamwork and collaboration, welcome change and creativity, encourage innovation

The Medanta Model of Healthcare

Delivering the highest quality of medicine with care and compassion




What it means for patients and caregivers?

- Super specialized doctors provide the highest quality of care through a team based integrated approach
- A safe and friendly healing environment with a patient-centric design in all clinical areas and public spaces
- Availability of the most advanced, innovative equipment and technology to enable the most complex diagnostics and treatment
- Doctors who take ownership and personal responsibility
- Respect-based processes for patients and their families

Medanta is well placed to deliver sustainable growth...

...while maintaining its core values of patient centric care and clinical leadership and quality



BED EXPANSION

In existing and new hospitals

ATTRACT BEST TALENT

Engage prominent, skilled clinical talent

ENHANCE CAPABILITIES

Add new specialties and improve operating efficiencies

TECHNOLOGY ADVANCEMENT

Use technology to improve patient experience and grow digital health

CONTINUITY OF CARE

Extend clinical services outside hospital and across patient lifetime

THOUGHT LEADERSHIP

Build on our thought leadership through academics and research

04 # Annexures

Annexure: Profit and Loss Statement

INR million	Half Year			Quarter			
	H1 FY2026	H1 FY2027	Y-o-Y Growth %	Q2FY2026	Q1FY2027	Q2FY2027	Y-o-Y Growth %
Revenue from operations	**21,301**	**27,731**	***30.2%***	**10,993**	**13,041**	**14,690**	***33.6%***
Cost of materials consumed	4,946	6,156	*24.5%*	2,556	2,944	3,213	*25.7%*
Employee benefits expense	8,045	10,550	*31.1%*	4,193	5,136	5,413	*29.1%*
Other expenses	3,551	4,330	*21.9%*	1,834	2,029	2,301	*25.4%*
ESOP Expenses	179	127	*(29.3)%*	100	64	63	*(37.2)%*
Operating EBITDA[1]	**4,580**	**6,568**	***43.4%***	**2,310**	**2,868**	**3,701**	***60.2%***
Operating EBITDA Margins %	**21.5%**	**23.7%**	***219 bps***	***21.0%***	***22.0%***	***25.2%***	***418 bps***
Other income	401	458	*14.1%*	197	222	236	*20.1%*
Finance costs	309	548	*77.2%*	171	267	281	*64.1%*
Depreciation and amortisation expense	948	1,398	*47.4%*	497	690	708	*42.4%*
Exceptional item	(356)	-	*Nm*	(160)	-	-	*nm*
Profit before tax	**4,080**	**5,081**	***24.5%***	**1,998**	**2,133**	**2,948**	***47.6%***
Tax expenses	906	1,317	*45.4%*	414	560	757	*82.7%*
Profit after tax	**3,174**	**3,764**	***18.6%***	**1,584**	**1,573**	**2,191**	***38.3%***

1. Operating EBITDA is defined as EBITDA excluding other income and after accounting for ESOP expenses. The comparative figures have also been presented on a consistent, like-for-like basis

Annexure: Operational Parameters

Key metrics	Year End			Quarter			
	H1 FY2026	H1 FY2027	Y-o-Y Growth %	Q2FY2026	Q1FY2027	Q2FY2027	Y-o-Y Growth %
Total Beds	3,435	3,811	*10.9%*	3,435	3,737	3,811	*10.9%*
Census Beds	2,573	3,076	*19.6%*	2,658	3,037	3,115	*17.2%*
Occupied Bed Days	2,98,627	3,63,664	*21.8%*	1,55,729	1,73,064	1,90,600	*22.4%*
Occupancy Rate %	*63.4%*	64.6%	*1.8%*	*63.7%*	*62.6%*	66.5%	*283 bps*
ARPP (INR Lakh)*	2.01	2.04	*1.5%*	2.01	2.02	2.06	*2.7%*
ALOS (days)	3.04	2.88	*(5.3)%*	3.06	2.87	2.89	*(5.5)%*
In-Patient Volumes	98,075	1,26,170	*28.6%*	50,925	60,214	65,956	*29.5%*
Out-Patient Volumes**	17,09,565	23,29,542	*36.3%*	8,90,750	11,00,928	12,28,614	*37.9%*

- Census Beds as based on monthly average during the period
- *ARPP is calculated on Hospital Revenues excluding Other Operating Income and other income divided by Inpatient Volumes;
- **Outpatients volume reflects OPD encounters

Annexure: Abbreviations and Definitions

Abbreviations

- INR : Indian Rupee
- NABH : National Accreditation Board for Hospitals & Healthcare Providers
- NABL : National Accreditation Board for Testing and Calibration Laboratories
- JCI : Joint Commission International
- OPD : Out-Patient Department
- IPD : In Patient Department
- ICU : Intensive Care Unit
- Mn : Million
- ARPP: Average Revenue per Inpatient
- ALOS : Average Length of Stay
- Operating EBITDA represents EBITDA excluding other income and after accounting for ESOP expenses.
- Operating EBITDA Margin : Operating EBITDA divided by Revenue from Operations in percentage
- PAT : Profit After Tax
- NCR : National Capital Region

Definitions

- Bed Capacity / Installed Beds : Total Bed available in the hospital (including census (bed available for mid-night occupancy) and non-census beds (all other bed available other than census beds, i.e., day-care beds).
- Occupied beds : Total Count of patients at midnight at each day
- Average Occupancy Levels : (Total Occupied beds/Total census beds) i.e. Excluding day Care bed, Emergency, Dialysis beds, Pre & post catherization & Observation room
- ICU Beds: No of ICU Beds available in the hospital out of census beds
- Total Income : Revenue from Operations + Other Income
- ARPP : Income from Health Care Services excluding Other Operating Income and Other Income divided by Inpatient Volume
- ALOS : Average number of days spent by admitted inpatients
- Revenue mix by Payment Type, i.e. Cash, TPA,CGHS, ECHS, PSU others

Contact us

About Medanta

Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third- and fourth-highest civilian awards in India, and the Dr. B.C. Roy Award in recognition of his distinguished contribution to medicine.

Global Health Limited (the "Company") is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, with key specialties cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology, according to the report titled "An assessment of the healthcare delivery market in India, September 2022" by CRISIL Limited.

Under the "Medanta" brand, the Company has a network of six hospitals currently in operation (Gurgaon, Indore, Ranchi, Lucknow, Patna and Noida). Spanning an area of 5.6 million sq. ft., its operational hospitals have 3,811 installed beds as on September 30, 2026. The Company provides healthcare services in over 30 medical specialties and engages over 2,580 doctors led by highly experienced department heads.

Contact Details

Gaurav Chugh

Head Investor Relations

+91 99585 88900

Gaurav.Chugh@Medanta.org

Corporate Office

Medanta; The Medicity
CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector 38, Gurgaon, Haryana 122001

For further information, please visit our website:

https://www.medanta.org/